SJEPD030388_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 6.09
- fusion
- other YAP1
- e1_e2
- E1
- umap1_2d
- -3.823931635
- umap2_2d
- 2.756939375
- umap1_3d
- -1.132675061
- umap2_3d
- 2.823362551
- umap3_3d
- -1.116557892
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.420
- TGF_BETA_SIGNALING+0.370
- HEDGEHOG_SIGNALING+0.200
- APICAL_SURFACE+0.190
- TNFA_SIGNALING_VIA_NFKB+0.150
- APICAL_JUNCTION+0.140
- UV_RESPONSE_UP+0.140
- ANGIOGENESIS+0.130
- WNT_BETA_CATENIN_SIGNALING+0.120
- ANDROGEN_RESPONSE+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.250
- E2F_TARGETS-0.220
- COAGULATION-0.210
- MTORC1_SIGNALING-0.190
- COMPLEMENT-0.170
- DNA_REPAIR-0.160
- HEME_METABOLISM-0.160
- BILE_ACID_METABOLISM-0.150
- KRAS_SIGNALING_UP-0.140
- MYOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5J9-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.580 |
| 2 | bb6e957d-5069-447e-95f0-5fcac2c5e744 | — | — | 0.561 |
| 3 | TCGA-AC-A8OP-01A-11R-A36F-07 | — | A | 0.545 |
| 4 | MNG238 | — | — | 0.537 |
| 5 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.534 |
| 6 | MNG1102 | — | — | 0.525 |
| 7 | SRR934947 | — | — | 0.519 |
| 8 | MNG109 | — | — | 0.512 |
| 9 | 0d373d8e-2507-4d88-8e19-d3f7b66955b4 | — | — | 0.507 |
| 10 | TCGA-BH-A28Q-01A-11R-A16F-07 | — | B | 0.506 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.420 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |